Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.

Expert review of anticancer therapy - 1 Apr 2021

Jacob Allen, Shook Jaret, Hutson Thomas

Abstract excerpt

Introduction: There are 400,000 new cases of Renal Cell Carcinoma (RCC) and 175,000 deaths worldwide every year. Currently available frontline therapies to treat RCC have less toxicity than previously employed therapeutic agents, but drug resistance is still a clinically significant problem. Drug resistance occurs through angiogenic escape by the activation of pathways that are independent of the VEGF targets of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Everolimus

Share to Kidney Neoplasms

Share to Phenylurea Compounds

Share to Progression-Free Survival

Share to Quinolines

Share to Survival Rate

Source

Identifiers

PMID: 33393393
DOI: 10.1080/14737140.2021.1868994

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.PMID 33393393Read ↗

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity Read ↗

Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-CarcinomaSemantic proximity Read ↗

Treatment strategies for clear cell renal cell carcinoma: Past, present and futureSemantic proximity Read ↗

Molecular basis for the treatment of renal cell carcinoma.Semantic proximity Read ↗

Molecular Mechanisms of Drug Resistance in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

Molecular Mechanisms of Targeted Therapy Resistance in Genitourinary Tumors: A Path to New Therapeutic HorizonsSemantic proximity Read ↗

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.Semantic proximity Read ↗

Kidney cancer pathology in the new context of targeted therapy.Semantic proximity Read ↗

PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.Semantic proximity Read ↗

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.Semantic proximity Read ↗

Current and future strategies in nonclear-cell metastatic renal cell carcinoma.Semantic proximity Read ↗

Current updates and future perspectives on the management of renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.